{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:03:38Z","timestamp":1794002618109,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41375-022-01511-6","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T12:03:16Z","timestamp":1643716996000},"page":"1025-1034","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3354-332X","authenticated-orcid":false,"given":"Thomas","family":"Hueso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Godron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Lanoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Pacanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura I.","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Gras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Surgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Guemriche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Meynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Pirenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Idri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Tiberghien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-7717","authenticated-orcid":false,"given":"Pascal","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-7173","authenticated-orcid":false,"given":"Caroline","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-1713","authenticated-orcid":false,"given":"R\u00e9my","family":"Dul\u00e9ry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-305X","authenticated-orcid":false,"given":"Sylvain","family":"Lamure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Gagneux-Brunon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Freymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Grabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8772-9029","authenticated-orcid":false,"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"1511_CR1","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","volume":"136","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881\u201392.","journal-title":"Blood"},{"key":"1511_CR2","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","volume":"26","author":"EV Robilotti","year":"2020","unstructured":"Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218\u201323.","journal-title":"Nat Med."},{"key":"1511_CR3","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:2291\u20133.","journal-title":"N Engl J Med"},{"key":"1511_CR4","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.annonc.2021.07.002","volume":"32","author":"JM Michot","year":"2021","unstructured":"Michot JM, Hueso T, Ibrahimi N, Pommeret F, Willekens C, Colomba E, et al. Severe COVID-19 in patients with hematological cancers presenting with viremia. Ann Oncol. 2021;32:1297\u2013300.","journal-title":"Ann Oncol"},{"key":"1511_CR5","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Y Herishanu","year":"2021","unstructured":"Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165\u201373.","journal-title":"Blood."},{"key":"1511_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00534-z","volume":"11","author":"F Malard","year":"2021","unstructured":"Malard F, Gaugler B, Gozlan J, Bouquet L, Fofana D, Siblany L, et al. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J. 2021;11:1\u20138.","journal-title":"Blood Cancer J"},{"key":"1511_CR7","doi-asserted-by":"publisher","first-page":"e150646","DOI":"10.1172\/JCI150646","volume":"131","author":"MR O\u2019Donnell","year":"2021","unstructured":"O\u2019Donnell MR, Grinsztejn B, Cummings MJ, Justman JE, Lamb MR, Eckhardt CM, et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J Clin Invest. 2021;131:e150646.","journal-title":"J Clin Invest"},{"key":"1511_CR8","doi-asserted-by":"publisher","first-page":"e155114","DOI":"10.1172\/JCI155114","volume":"131","author":"KJ Bar","year":"2021","unstructured":"Bar KJ, Shaw PA, Choi GH, Aqui N, Fesnak A, Yang JB, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest. 2021;131:e155114.","journal-title":"J Clin Invest"},{"key":"1511_CR9","doi-asserted-by":"publisher","first-page":"e152740","DOI":"10.1172\/JCI152740","volume":"131","author":"C Avenda\u00f1o-Sol\u00e1","year":"2021","unstructured":"Avenda\u00f1o-Sol\u00e1 C, Ramos-Mart\u00ednez A, Mu\u00f1ez-Rubio E, Ruiz-Antor\u00e1n B, Malo de Molina R, Torres F, et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest. 2021;131:e152740.","journal-title":"J Clin Invest"},{"key":"1511_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1001\/jama.2021.2747","volume":"325","author":"P Janiaud","year":"2021","unstructured":"Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021;325:1185\u201395.","journal-title":"JAMA."},{"key":"1511_CR11","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/blood.2020008423","volume":"136","author":"T Hueso","year":"2020","unstructured":"Hueso T, Pouderoux C, P\u00e9r\u00e9 H, Beaumont A-L, Raillon L-A, Ader F, et al. Convalescent plasma therapy for B-cell\u2013depleted patientswith protracted COVID-19. Blood. 2020;136:2290\u20135.","journal-title":"Blood."},{"key":"1511_CR12","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","volume":"7","author":"MA Thompson","year":"2021","unstructured":"Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, et al. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol. 2021;7:1167\u201375.","journal-title":"JAMA Oncol"},{"key":"1511_CR13","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamaoncol.2021.1715","volume":"7","author":"GS Calip","year":"2021","unstructured":"Calip GS, Miksad RA, Sarkar S. Time-related biases in nonrandomized COVID-19\u2013era studies using real-world data. JAMA Oncol. 2021;7:1175\u20137.","journal-title":"JAMA Oncol"},{"key":"1511_CR14","doi-asserted-by":"crossref","unstructured":"Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Res. 2020;181:104880.","DOI":"10.1016\/j.antiviral.2020.104880"},{"key":"1511_CR15","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","volume":"20","author":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection.","year":"2020","unstructured":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192\u201397.","journal-title":"Lancet Infect Dis"},{"key":"1511_CR16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/ajh.26209","volume":"96","author":"R Dul\u00e9ry","year":"2021","unstructured":"Dul\u00e9ry R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96:934\u201344.","journal-title":"Am J Hematol"},{"key":"1511_CR17","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1172\/JCI140200","volume":"130","author":"MJ Joyner","year":"2020","unstructured":"Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130:4791\u20137.","journal-title":"J Clin Invest"},{"key":"1511_CR18","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737\u201345.","journal-title":"Lancet Haematol"},{"key":"1511_CR19","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1182\/blood.2020008963","volume":"136","author":"MF Murphy","year":"2020","unstructured":"Murphy MF, Dzik S. COVID-19, plasma, and hypogammaglobulinemia. Blood 2020;136:2245\u20136.","journal-title":"Blood"},{"key":"1511_CR20","unstructured":"Writing Committee for the REMAP-CAP Investigators. Effect of convalescent plasma on organ support-free days in critically Ill patients with COVID-19: a randomized clinical trial. JAMA. 2021;326:1690\u2013702."},{"key":"1511_CR21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa2033700","volume":"384","author":"R Libster","year":"2021","unstructured":"Libster R, P\u00e9rez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med. 2021;384:610\u20138.","journal-title":"N Engl J Med"},{"key":"1511_CR22","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","volume":"397","author":"RECOVERY Collaborative Group.","year":"2021","unstructured":"RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397:2049\u201359.","journal-title":"Lancet"},{"key":"1511_CR23","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.chom.2021.06.001","volume":"29","author":"A Tauzin","year":"2021","unstructured":"Tauzin A, Nayrac M, Benlarbi M, Gong SY, Gasser R, Beaudoin-Bussi\u00e8res G, et al. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host Microbe. 2021;29:1137.e6.","journal-title":"Cell Host Microbe"},{"key":"1511_CR24","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1126\/science.abg9175","volume":"372","author":"L Stamatatos","year":"2021","unstructured":"Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372:1413\u20138.","journal-title":"Science."},{"key":"1511_CR25","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","volume":"184","author":"C Liu","year":"2021","unstructured":"Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184:4220.e13.","journal-title":"Cell."},{"key":"1511_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.mayocp.2021.11.001","volume":"97","author":"EE Ordaya","year":"2022","unstructured":"Ordaya EE, Abu Saleh OM, Stubbs JR, Joyner MJ. Vax-plasma in patients with refractory COVID-19. Mayo Clin Proc. 2022;97:186\u20139.","journal-title":"Mayo Clin Proc"},{"key":"1511_CR27","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"1511_CR28","unstructured":"Horby PW, Mafham M, Peto L, Campbell M, Pessoa-Amorim G, Spata E, et al. Casirivimab and imdevimab in patients admitted to 4 hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]. 2021."},{"key":"1511_CR29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","volume":"39","author":"A Thakkar","year":"2021","unstructured":"Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39:1081.e2.","journal-title":"Cancer Cell"},{"key":"1511_CR30","doi-asserted-by":"crossref","unstructured":"Terpos E, Trougakos IP, Gavriatopoulou M, Papassotiriou I, Sklirou AD, Ntanasis-Stathopoulos I, et al. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021;137:3674\u20136.","DOI":"10.1182\/blood.2021011904"},{"key":"1511_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N Engl J Med. 2021;384:238\u201351.","journal-title":"N Engl J Med"},{"key":"1511_CR32","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.annonc.2021.07.015","volume":"32","author":"F Pommeret","year":"2021","unstructured":"Pommeret F, Colomba J, Bigenwald C, Laparra A, Bockel S, Bayle A, et al. Bamlanivimab+etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies. Ann Oncol. 2021;32:1445\u20137.","journal-title":"Ann Oncol"},{"key":"1511_CR33","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1093\/cid\/ciab392","volume":"73","author":"B Lohr","year":"2021","unstructured":"Lohr B, Niemann D, Verheyen J. Bamlanivimab treatment leads to rapid selection of immune escape variant carrying the E484K mutation in a B.1.1.7-infected and immunosuppressed patient. Clin Infect Dis. 2021;73:2144\u20135.","journal-title":"Clin Infect Dis"},{"key":"1511_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","volume":"592","author":"SA Kemp","year":"2021","unstructured":"Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592:277\u201382.","journal-title":"Nature"},{"key":"1511_CR35","doi-asserted-by":"publisher","first-page":"e1762","DOI":"10.1093\/cid\/ciaa1474","volume":"73","author":"M Martinot","year":"2021","unstructured":"Martinot M, Jary A, Fafi-Kremer S, Leducq V, Delagreverie H, Garnier M, et al. Emerging RNA-dependent RNA polymerase mutation in a remdesivir-treated B-cell immunodeficient patient with protracted coronavirus disease 2019. Clin Infect Dis. 2021;73:e1762\u2013e1765.","journal-title":"Clin Infect Dis"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01511-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T07:15:22Z","timestamp":1649056522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01511-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1511"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01511-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.29.21268525","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"assertion":[{"value":"25 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}